LUND, Sweden, Jan 23, 2017 /PRNewswire/ --
The Board of Directors of BioInvent International AB (OMXS: BINV) announces that the Extraordinary General Meeting to be held January 24, 2017, is cancelled. The Board intends instead to present the proposal for an incentive program for shareholder approval at the Annual General Meeting to be held on May 17, 2017.
Notes to editors:
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials.
For further information, please contact:
President and CEO
Tel: +46 (0)46-286-85-67 or +46 (0)707-16-89-30
Björn O. Nilsson
Chairman of the Board
Tel: +46 (0)70-218-15-00
Citigate Dewe Rogerson
David Dible/Katja Stout/ Marine Perrier
Tel: +44 (0)20-7638-957-1
BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46-286-85-50
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: